RTI uses cookies to offer you the best experience online. By clicking “accept” on this website, you opt in and you agree to the use of cookies. If you would like to know more about how RTI uses cookies and how to manage them please view our Privacy Policy here. You can “opt out” or change your mind by visiting: http://optout.aboutads.info/. Click “accept” to agree.
The statistical design and analysis of pandemic platform trials
Implications for the future
Lindsell, C. J., Shotwell, M., Anstrom, K. J., Berry, S., Brittain, E., Harrell, F. E., Geller, N., Grund, B., Hughes, M. D., Jagannathan, P., Leifer, E., Moser, C. B., Price, K. L., Proschan, M., Stewart, T., Thomas, S., Touloumi, G., & LaVange, L. (2024). The statistical design and analysis of pandemic platform trials: Implications for the future. Journal of Clinical and Translational Science, 8(1), Article e155. https://doi.org/10.1017/cts.2024.514
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Cross-Trial Statistics Group gathered lessons learned from statisticians responsible for the design and analysis of the 11 ACTIV therapeutic master protocols to inform contemporary trial design as well as preparation for a future pandemic. The ACTIV master protocols were designed to rapidly assess what treatments might save lives, keep people out of the hospital, and help them feel better faster. Study teams initially worked without knowledge of the natural history of disease and thus without key information for design decisions. Moreover, the science of platform trial design was in its infancy. Here, we discuss the statistical design choices made and the adaptations forced by the changing pandemic context. Lessons around critical aspects of trial design are summarized, and recommendations are made for the organization of master protocols in the future.
